Adult T-cell leukemia-lymphoma · 4 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
LSG15 Variant #01 Partial | — | R 3 088 | 28d | — | — | ~7 | ~R 21 614 indirect | — |
mLSG15 Variant #01 Partial | — | R 3 088 | 28d | — | — | ~6 | ~R 18 526 indirect | — |
CHOP-14 Variant #01 | — | R 1 166 | 14d | — | ~10.9 mo | ~6 | ~R 6 997 PFS proxy · indirect | — |
Interferon alfa-2b and Zidovudine Variant #01 Partial | — | R 67 | 7d | — | — | ~7 | ~R 470 indirect | — |
4 of 4 regimens shown